priority review

November 16, 2018

FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review the use of Lynparza (olaparib) tablets as a maintenance treatment for women newly diagnosed with advanced ovarian cancer, Merck announced ... Read more

August 26, 2016August 26, 2016

Rucaparib for Advanced BRCA–Mutated Ovarian Cancer Granted FDA Priority Review

News

The US Food and Drug Administration (FDA) has recently granted priority review to Rucaparib for the treatment of patients with advanced ovarian cancer who have germline or somatic BRCA–mutated tumors. Rucaparib was ... Read more